The Friendswood-based firm, known for its suite of molecular tests including DecisionDx-Melanoma and TissueCypher, maintains a focus on providing clinicians with actionable data for treatment planning. Management plans to deliver a comprehensive company overview, highlighting how its personalized diagnostic solutions aim to improve patient outcomes. Investors and interested parties can follow the session via a live audio webcast hosted on the company’s investor relations website, with a replay scheduled for release shortly after the broadcast concludes.
In section Releases
Castle Biosciences to Outline Growth Strategy at Canaccord Conference
Executives from Castle Biosciences will take the stage on August 12 at the Canaccord Genuity 46th Annual Growth Conference. The presentation, set for 11:30 a.m. Eastern time, serves as a platform for the diagnostics company to detail its clinical progress in dermatologic and gastroenterological disease management to prospective investors.
Comments (0)
No comments yet. Be the first!